The funding brings together an international team of executives and investors with an extensive track record for developing ophthalmology therapies. EyeBio launched with a specific mission, to protect, restore, and improve vision for people who are underserved by available eye disease therapies. The company has established a footprint in the U.K. to take advantage of the innovation-friendly environment for its clinical trial development.

The EyeBio management team combines deep experience in ophthalmology with proven innovation and success in clinical development. EyeBio is a privately held ophthalmology biotechnology company dedicated to developing and delivering a new generation of therapies to protect, restore, and improve vision in patients with sight-threatening eye diseases.

SV Health Investors led the round, alongside Samsara BioCapital and Jeito Capital, with additional financial backing from MRL Ventures.

Optogenetic gene therapy provides hope for retinitis pigmentosa patients
Optogenetic therapy bypasses traditional methods of repairing defective photoreceptors in the eye by targeting other retinal cells. Recently, three examples...

ViGeneron, Biogen to develop AAV-based gene therapies for eye disease
ViGeneron and Biogen have signed a global collaboration and licensing agreement to develop and commercialize gene therapy products based on adeno-associated...

Gyroscope partners with UPenn for gene therapies targeting eye disease
Gyroscope Therapeutics has entered into a sponsored research agreement with the University of Pennsylvania (UPenn) and the Penn Center for Advanced Retinal...

Researchers explore role of cytokine storm in severe COVID-19
An overreaction of the immune system to SARS-CoV-2 -- a phenomenon known as cytokine storm -- has emerged as a major contributor to patient mortality...